Bloomberg - Drug developer Depomed Inc. said Monday that President and CEO Carl A. Pelzel resigned for personal reasons and will be replaced by board member James A. Schoeneck.
The Menlo Park, Calif., company said Schoeneck, 53, joined the company's board in 2007. He has served as CEO of BrainCells Inc., a private biopharmaceutical company, since 2005.
